

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Ashkenazi et al.
App. No. : 09/903,925
Filed : July 11, 2001
For : SECRETED AND
TRANSMEMBRANE
POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME
Examiner : Hamud, Fozia M

Group Art Unit 1647

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner of Patents, Washington D.C. 20231 on:

(Date)

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DECLARATION OF AVI ASHKENAZI, Ph.D UNDER 37 C.F.R. § 1.132

I, Avi Ashkenazi, Ph.D. declare and say as follows: -

1. I am Director and Staff Scientist at the Molecular Oncology Department of Genentech, Inc., South San Francisco, CA 94080.
2. I joined Genentech in 1988 as a postdoctoral fellow. Since then, I have investigated a variety of cellular signal transduction mechanisms, including apoptosis, and have developed technologies to modulate such mechanisms as a means of therapeutic intervention in cancer and autoimmune disease. I am currently involved in the investigation of a series of secreted proteins over-expressed in tumors, with the aim to identify useful targets for the development of therapeutic antibodies for cancer treatment.
3. My scientific Curriculum Vitae, including my list of publications, is attached to and forms part of this Declaration (Exhibit A).
4. Gene amplification is a process in which chromosomes undergo changes to contain multiple copies of certain genes that normally exist as a single copy, and is an important factor in the pathophysiology of cancer. Amplification of certain genes (e.g., Myc or Her2/Neu)

gives cancer cells a growth or survival advantage relative to normal cells, and might also provide a mechanism of tumor cell resistance to chemotherapy or radiotherapy.

5. If gene amplification results in over-expression of the mRNA and the corresponding gene product, then it identifies that gene product as a promising target for cancer therapy, for example by the therapeutic antibody approach. Even in the absence of over-expression of the gene product, amplification of a cancer marker gene - as detected, for example, by the reverse transcriptase TaqMan[®] PCR or the fluorescence *in situ* hybridization (FISH) assays - is useful in the diagnosis or classification of cancer, or in predicting or monitoring the efficacy of cancer therapy. An increase in gene copy number can result not only from intrachromosomal changes but also from chromosomal aneuploidy. It is important to understand that detection of gene amplification can be used for cancer diagnosis even if the determination includes measurement of chromosomal aneuploidy. Indeed, as long as a significant difference relative to normal tissue is detected, it is irrelevant if the signal originates from an increase in the number of gene copies per chromosome and/or an abnormal number of chromosomes.

6. I understand that according to the Patent Office, absent data demonstrating that the increased copy number of a gene in certain types of cancer leads to increased expression of its product, gene amplification data are insufficient to provide substantial utility or well established utility for the gene product (the encoded polypeptide), or an antibody specifically binding the encoded polypeptide. However, even when amplification of a cancer marker gene does not result in significant over-expression of the corresponding gene product, this very absence of gene product over-expression still provides significant information for cancer diagnosis and treatment. Thus, if over-expression of the gene product does not parallel gene amplification in certain tumor types but does so in others, then parallel monitoring of gene amplification and gene product over-expression enables more accurate tumor classification and hence better determination of suitable therapy. In addition, absence of over-expression is crucial information for the practicing clinician. If a gene is amplified but the corresponding gene product is not over-expressed, the clinician accordingly will decide not to treat a patient with agents that target that gene product.

7. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so

made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

By: Avi Ashkenazi
Avi Ashkenazi, Ph.D.

Date: 9/15/03

CURRICULUM VITAE

Avi Ashkenazi

July 2003

Personal:

Date of birth: 29 November, 1956
Address: 1456 Tarrytown Street, San Mateo, CA 94402
Phone: (650) 578-9199 (home); (650) 225-1853 (office)
Fax: (650) 225-6443 (office)
Email: aa@gene.com

Education:

1983: B.S. in Biochemistry, with honors, Hebrew University, Israel
1986: Ph.D. in Biochemistry, Hebrew University, Israel

Employment:

1983-1986: Teaching assistant, undergraduate level course in Biochemistry
1985-1986: Teaching assistant, graduate level course on Signal Transduction
1986 - 1988: Postdoctoral fellow, Hormone Research Dept., UCSF, and
Developmental Biology Dept., Genentech, Inc., with J. Ramachandran
1988 - 1989: Postdoctoral fellow, Molecular Biology Dept., Genentech, Inc.,
with D. Capon
1989 - 1993: Scientist, Molecular Biology Dept., Genentech, Inc.
1994 -1996: Senior Scientist, Molecular Oncology Dept., Genentech, Inc.
1996-1997: Senior Scientist and Interim director, Molecular Oncology Dept.,
Genentech, Inc.
1997-1990: Senior Scientist and preclinical project team leader, Genentech, Inc.
1999 -2002: Staff Scientist in Molecular Oncology, Genentech, Inc.
2002-present: Staff Scientist and Director in Molecular Oncology, Genentech, Inc.

Awards:

1988: First prize, The Boehringer Ingelheim Award

Editorial:

Editorial Board Member: Current Biology

Associate Editor, Clinical Cancer Research.

Associate Editor, Cancer Biology and Therapy.

Refereed papers:

1. Gertler, A., Ashkenazi, A., and Madar, Z. Binding sites for human growth hormone and ovine and bovine prolactins in the mammary gland and liver of the lactating cow. *Mol. Cell. Endocrinol.* **34**, 51-57 (1984).
2. Gertler, A., Shamay, A., Cohen, N., Ashkenazi, A., Friesen, H., Levanon, A., Gorecki, M., Aviv, H., Hadari, D., and Vogel, T. Inhibition of lactogenic activities of ovine prolactin and human growth hormone (hGH) by a novel form of a modified recombinant hGH. *Endocrinology* **118**, 720-726 (1986).
3. Ashkenazi, A., Madar, Z., and Gertler, A. Partial purification and characterization of bovine mammary gland prolactin receptor. *Mol. Cell. Endocrinol.* **50**, 79-87 (1987).
4. Ashkenazi, A., Pines, M., and Gertler, A. Down-regulation of lactogenic hormone receptors in Nb2 lymphoma cells by cholera toxin. *Biochemistry Internatl.* **14**, 1065-1072 (1987).
5. Ashkenazi, A., Cohen, R., and Gertler, A. Characterization of lactogen receptors in lactogenic hormone-dependent and independent Nb2 lymphoma cell lines. *FEBS Lett.* **210**, 51-55 (1987).
6. Ashkenazi, A., Vogel, T., Barash, I., Hadari, D., Levanon, A., Gorecki, M., and Gertler, A. Comparative study on in vitro and in vivo modulation of lactogenic and somatotrophic receptors by native human growth hormone and its modified recombinant analog. *Endocrinology* **121**, 414-419 (1987).
7. Peralta, E., Winslow, J., Peterson, G., Smith, D., Ashkenazi, A., Ramachandran, J., Schimerlik, M., and Capon, D. Primary structure and biochemical properties of an M2 muscarinic receptor. *Science* **236**, 600-605 (1987).
8. Peralta, E., Ashkenazi, A., Winslow, J., Smith, D., Ramachandran, J., and Capon, D. J. Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. *EMBO J.* **6**, 3923-3929 (1987).
9. Ashkenazi, A., Winslow, J., Peralta, E., Peterson, G., Schimerlik, M., Capon, D., and Ramachandran, J. An M2 muscarinic receptor subtype coupled to both adenylyl cyclase and phosphoinositide turnover. *Science* **238**, 672-675 (1987).

10. Pines, M., Ashkenazi, A., Cohen-Chapnik, N., Binder, L., and Gertler, A. Inhibition of the proliferation of Nb2 lymphoma cells by femtomolar concentrations of cholera toxin and partial reversal of the effect by 12-o-tetradecanoyl-phorbol-13-acetate. *J. Cell. Biochem.* **37**, 119-129 (1988).
11. Peralta, E., Ashkenazi, A., Winslow, J., Ramachandran, J., and Capon, D. Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes. *Nature* **334**, 434-437 (1988).
12. Ashkenazi, A., Peralta, E., Winslow, J., Ramachandran, J., and Capon, D. Functionally distinct G proteins couple different receptors to PI hydrolysis in the same cell. *Cell* **56**, 487-493 (1989).
13. Ashkenazi, A., Ramachandran, J., and Capon, D. Acetylcholine analogue stimulates DNA synthesis in brain-derived cells via specific muscarinic acetylcholine receptor subtypes. *Nature* **340**, 146-150 (1989).
14. Lammare, D., Ashkenazi, A., Fleury, S., Smith, D., Sekaly, R., and Capon, D. The MHC-binding and gp120-binding domains of CD4 are distinct and separable. *Science* **245**, 743-745 (1989).
15. Ashkenazi, A., Presta, L., Marsters, S., Camerato, T., Rosenthal, K., Fendly, B., and Capon, D. Mapping the CD4 binding site for human immunodeficiency virus type 1 by alanine-scanning mutagenesis. *Proc. Natl. Acad. Sci. USA.* **87**, 7150-7154 (1990).
16. Chamow, S., Peers, D., Byrn, R., Mulkerrin, M., Harris, R., Wang, W., Bjorkman, P., Capon, D., and Ashkenazi, A. Enzymatic cleavage of a CD4 immunoadhesin generates crystallizable, biologically active Fd-like fragments. *Biochemistry* **29**, 9885-9891 (1990).
17. Ashkenazi, A., Smith, D., Marsters, S., Riddle, L., Gregory, T., Ho, D., and Capon, D. Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity. *Proc. Natl. Acad. Sci. USA.* **88**, 7056-7060 (1991).
18. Ashkenazi, A., Marsters, S., Capon, D., Chamow, S., Figari, I., Pennica, D., Goeddel, D., Palladino, M., and Smith, D. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. *Proc. Natl. Acad. Sci. USA.* **88**, 10535-10539 (1991).
19. Moore, J., McKeating, J., Huang, Y., Ashkenazi, A., and Ho, D. Virions of primary HIV-1 isolates resistant to sCD4 neutralization differ in sCD4 affinity and glycoprotein gp120 retention from sCD4-sensitive isolates. *J. Virol.* **66**, 235-243 (1992).

20. Jin, H., Oksenberg, D., Ashkenazi, A., Peroutka, S., Duncan, A., Rozmahel, R., Yang, Y., Mengod, G., Palacios, J., and O'Dowd, B. Characterization of the human 5-hydroxytryptamine_{1B} receptor. *J. Biol. Chem.* **267**, 5735-5738 (1992).
21. Marsters, A., Frutkin, A., Simpson, N., Fendly, B. and Ashkenazi, A. Identification of cysteine-rich domains of the type 1 tumor necrosis receptor involved in ligand binding. *J. Biol. Chem.* **267**, 5747-5750 (1992).
22. Chamow, S., Kogan, T., Peers, D., Hastings, R., Byrn, R., and Ashkenazi, A. Conjugation of sCD4 without loss of biological activity via a novel carbohydrate-directed cross-linking reagent. *J. Biol. Chem.* **267**, 15916-15922 (1992).
23. Oksenberg, D., Marsters, A., O'Dowd, B., Jin, H., Havlik, S., Peroutka, S., and Ashkenazi, A. A single amino-acid difference confers major pharmacologic variation between human and rodent 5-HT_{1B} receptors. *Nature* **360**, 161-163 (1992).
24. Haak-Frendscho, M., Marsters, S., Chamow, S., Peers, D., Simpson, N., and Ashkenazi, A. Inhibition of interferon γ by an interferon γ receptor immunoadhesin. *Immunology* **79**, 594-599 (1993).
25. Penica, D., Lam, V., Weber, R., Kohr, W., Basa, L., Spellman, M., Ashkenazi, A., Shire, S., and Goeddel, D. Biochemical characterization of the extracellular domain of the 75-kd tumor necrosis factor receptor. *Biochemistry* **32**, 3131-3138 (1993).
26. Barford, L., Zheng, Y., Kuang, W., Hart, M., Evans, T., Cerione, R., and Ashkenazi, A. Cloning and expression of a human CDC42 GTPase Activating Protein reveals a functional SH3-binding domain. *J. Biol. Chem.* **268**, 26059-26062 (1993).
27. Chamow, S., Zhang, D., Tan, X., Mhtre, S., Marsters, S., Peers, D., Byrn, R., Ashkenazi, A., and Yunghans, R. A humanized bispecific immunoadhesin-antibody that retargets CD3⁺ effectors to kill HIV-1-infected cells. *J. Immunol.* **153**, 4268-4280 (1994).
28. Means, R., Krantz, S., Luna, J., Marsters, S., and Ashkenazi, A. Inhibition of murine erythroid colony formation in vitro by interferon γ and correction by interferon γ receptor immunoadhesin. *Blood* **83**, 911-915 (1994).
29. Haak-Frendscho, M., Marsters, S., Mordenti, J., Gillet, N., Chen, S., and Ashkenazi, A. Inhibition of TNF by a TNF receptor immunoadhesin: comparison with an anti-TNF mAb. *J. Immunol.* **152**, 1347-1353 (1994).

30. Chamow, S., Kogan, T., Venuti, M., Gadek, T., Peers, D., Mordenti, J., Shak, S., and Ashkenazi, A. Modification of CD4 immunoadhesin with monomethoxy-PEG aldehyde via reductive alkylation. *Bioconj. Chem.* **5**, 133-140 (1994).
31. Jin, H., Yang, R., Marsters, S., Bunting, S., Wurm, F., Chamow, S., and Ashkenazi, A. Protection against rat endotoxic shock by p55 tumor necrosis factor (TNF) receptor immunoadhesin: comparison to anti-TNF monoclonal antibody. *J. Infect. Diseases* **170**, 1323-1326 (1994).
32. Beck, J., Marsters, S., Harris, R., Ashkenazi, A., and Chamow, S. Generation of soluble interleukin-1 receptor from an immunoadhesin by specific cleavage. *Mol. Immunol.* **31**, 1335-1344 (1994).
33. Pitti, B., Marsters, M., Haak-Frendscho, M., Osaka, G., Mordenti, J., Chamow, S., and Ashkenazi, A. Molecular and biological properties of an interleukin-1 receptor immunoadhesin. *Mol. Immunol.* **31**, 1345-1351 (1994).
34. Oksenberg, D., Havlik, S., Peroutka, S., and Ashkenazi, A. The third intracellular loop of the 5-HT₂ receptor specifies effector coupling. *J. Neurochem.* **64**, 1440-1447 (1995).
35. Bach, E., Szabo, S., Dighe, A., Ashkenazi, A., Aguet, M., Murphy, K., and Schreiber, R. Ligand-induced autoregulation of IFN- γ receptor β chain expression in T helper cell subsets. *Science* **270**, 1215-1218 (1995).
36. Jin, H., Yang, R., Marsters, S., Ashkenazi, A., Bunting, S., Marra, M., Scott, R., and Baker, J. Protection against endotoxic shock by bactericidal/permeability-increasing protein in rats. *J. Clin. Invest.* **95**, 1947-1952 (1995).
37. Marsters, S., Penica, D., Bach, E., Schreiber, R., and Ashkenazi, A. Interferon γ signals via a high-affinity multisubunit receptor complex that contains two types of polypeptide chain. *Proc. Natl. Acad. Sci. USA.* **92**, 5401-5405 (1995).
38. Van Zee, K., Moldawer, L., Oldenburg, H., Thompson, W., Stackpole, S., Montegut, W., Rogy, M., Meschter, C., Gallati, H., Schiller, C., Richter, W., Loetcher, H., Ashkenazi, A., Chamow, S., Wurm, F., Calvano, S., Lowry, S., and Lesslauer, W. Protection against lethal E. coli bacteremia in baboons by pretreatment with a 55-kDa TNF receptor-Ig fusion protein, Ro45-2081. *J. Immunol.* **156**, 2221-2230 (1996).
39. Pitti, R., Marsters, S., Ruppert, S., Donahue, C., Moore, A., and Ashkenazi, A. Induction of apoptosis by Apo-2 Ligand, a new member of the tumor necrosis factor cytokine family. *J. Biol. Chem.* **271**, 12687-12690 (1996).

40. Marsters, S., Pitti, R., Donahue, C., Rupert, S., Bauer, K., and Ashkenazi, A. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. *Curr. Biol.* **6**, 1669-1676 (1996).
41. Marsters, S., Skubatch, M., Gray, C., and Ashkenazi, A. Herpesvirus entry mediator, a novel member of the tumor necrosis factor receptor family, activates the NF- κ B and AP-1 transcription factors. *J. Biol. Chem.* **272**, 14029-14032 (1997).
42. Sheridan, J., Marsters, S., Pitti, R., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C., Baker, K., Wood, W.I., Goddard, A., Godowski, P., and Ashkenazi, A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. *Science* **277**, 818-821 (1997).
43. Marsters, S., Sheridan, J., Pitti, R., Gurney, A., Skubatch, M., Balswin, D., Huang, A., Yuan, J., Goddard, A., Godowski, P., and Ashkenazi, A. A novel receptor for Apo2L/TRAIL contains a truncated death domain. *Curr. Biol.* **7**, 1003-1006 (1997).
44. Marsters, A., Sheridan, J., Pitti, R., Brush, J., Goddard, A., and Ashkenazi, A. Identification of a ligand for the death-domain-containing receptor Apo3. *Curr. Biol.* **8**, 525-528 (1998).
45. Rieger, J., Naumann, U., Glaser, T., Ashkenazi, A., and Weller, M. Apo2 ligand: a novel weapon against malignant glioma? *FEBS Lett.* **427**, 124-128 (1998).
46. Pender, S., Fell, J., Chamow, S., Ashkenazi, A., and MacDonald, T. A p55 TNF receptor immunoadhesin prevents T cell mediated intestinal injury by inhibiting matrix metalloproteinase production. *J. Immunol.* **160**, 4098-4103 (1998).
47. Pitti, R., Marsters, S., Lawrence, D., Roy, Kischkel, F., M., Dowd, P., Huang, A., Donahue, C., Sherwood, S., Baldwin, D., Godowski, P., Wood, W., Gurney, A., Hillan, K., Cohen, R., Goddard, A., Botstein, D., and Ashkenazi, A. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. *Nature* **396**, 699-703 (1998).
48. Mori, S., Marakami-Mori, K., Nakamura, S., Ashkenazi, A., and Bonavida, B. Sensitization of AIDS Kaposi's sarcoma cells to Apo-2 ligand-induced apoptosis by actinomycin D. *J. Immunol.* **162**, 5616-5623 (1999).
49. Gurney, A. Marsters, S., Huang, A., Pitti, R., Mark, M., Baldwin, D., Gray, A., Dowd, P., Brush, J., Heldens, S., Schow, P., Goddard, A., Wood, W., Baker, K., Godowski, P., and Ashkenazi, A. Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. *Curr. Biol.* **9**, 215-218 (1999).

50. Ashkenazi, A., Pai, R., Fong, s., Leung, S., Lawrence, D., Marsters, S., Blackie, C., Chang, L., McMurtrey, A., Hebert, A., DeForge, L., Khoumenis, I., Lewis, D., Harris, L., Bussiere, J., Koeppen, H., Shahrokh, Z., and Schwall, R. Safety and anti-tumor activity of recombinant soluble Apo2 ligand. *J. Clin. Invest.* **104**, 155-162 (1999).
51. Chuntharapai, A., Gibbs, V., Lu, J., Ow, A., Marsters, S., Ashkenazi, A., De Vos, A., Kim, K.J. Determination of residues involved in ligand binding and signal transmissiion in the human IFN- α receptor 2. *J. Immunol.* **163**, 766-773 (1999).
52. Johnsen, A.-C., Haux, J., Steinkjer, B., Nonstad, U., Egeberg, K., Sundan, A., Ashkenazi, A., and Espevik, T. Regulation of Apo2L/TRAIL expression in NK cells – involvement in NK cell-mediated cytotoxicity. *Cytokine* **11**, 664-672 (1999).
53. Roth, W., Isenmann, S., Naumann, U., Kugler, S., Bahr, M., Dichgans, J., Ashkenazi, A., and Weller, M. Eradication of intracranial human malignant glioma xenografts by Apo2L/TRAIL. *Biochem. Biophys. Res. Commun.* **265**, 479-483 (1999).
54. Hymowitz, S.G., Christinger, H.W., Fuh, G., Ultsch, M., O'Connell, M., Kelley, R.F., Ashkenazi, A. and de Vos, A.M. Triggering Cell Death: The Crystal Structure of Apo2L/TRAIL in a Complex with Death Receptor 5. *Molec. Cell* **4**, 563–571 (1999).
55. Hymowitz, S.G., O'Connel, M.P., Utsch, M.H., Hurst, A., Totpal, K., Ashkenazi, A., de Vos, A.M., Kelley, R.F. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. *Biochemistry* **39**, 633-640 (2000).
56. Zhou, Q., Fukushima, P., DeGraff, W., Mitchell, J.B., Stetler-Stevenson, M., Ashkenazi, A., and Steeg, P.S. Radiation and the Apo2L/TRAIL apoptotic pathway preferentially inhibit the colonization of premalignant human breast cancer cells overexpressing cyclin D1. *Cancer Res.* **60**, 2611-2615 (2000).
57. Kischkel, F.C., Lawrence, D. A., Chuntharapai, A., Schow, P., Kim, J., and Ashkenazi, A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and Caspase-8 to death receptors 4 and 5. *Immunity* **12**, 611-620 (2000).
58. Yan, M., Marsters, S.A., Grewal, I.S., Wang, H., *Ashkenazi, A., and *Dixit, V.M. Identification of a receptor for BlyS demonstrates a crucial role in humoral immunity. *Nature Immunol.* **1**, 37-41 (2000).

59. Marsters, S.A., Yan, M., Pitti, R.M., Haas, P.E., Dixit, V.M., and Ashkenazi, A. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. *Curr. Biol.* **10**, 785-788 (2000).
60. Kischkel, F.C., and Ashkenazi, A. Combining enhanced metabolic labeling with immunoblotting to detect interactions of endogenous cellular proteins. *Biotechniques* **29**, 506-512 (2000).
61. Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D. Mounho, B., Hillan, K., Totpal, K. DeForge, L., Schow, P., Hooley, J., Sherwood, S., Pai, R., Leung, S., Khan, L., Gliniak, B., Bussiere, J., Smith, C., Strom, S., Kelley, S., Fox, J., Thomas, D., and Ashkenazi, A. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. *Nature Med.* **7**, 383-385 (2001).
62. Chuntharapai, A., Dodge, K., Grimmer, K., Schroeder, K., Martsters, S.A., Koeppen, H., Ashkenazi, A., and Kim, K.J. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. *J. Immunol.* **166**, 4891-4898 (2001).
63. Pollack, I.F., Erff, M., and Ashkenazi, A. Direct stimulation of apoptotic signaling by soluble Apo2L/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. *Clin. Cancer Res.* **7**, 1362-1369 (2001).
64. Wang, H., Marsters, S.A., Baker, T., Chan, B., Lee, W.P., Fu, L., Tumas, D., Yan, M., Dixit, V.M., *Ashkenazi, A., and *Grewal, I.S. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. *Nature Immunol.* **2**, 632-637 (2001).
65. Kischkel, F.C., Lawrence, D. A., Tinel, A., Virmani, A., Schow, P., Gazdar, A., Blenis, J., Arnott, D., and Ashkenazi, A. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. *J. Biol. Chem.* **276**, 46639-46646 (2001).
66. LeBlanc, H., Lawrence, D.A., Varfolomeev, E., Totpal, K., Morlan, J., Schow, P., Fong, S., Schwall, R., Sinicropi, D., and Ashkenazi, A. Tumor cell resistance to death receptor induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. *Nature Med.* **8**, 274-281 (2002).
67. Miller, K., Meng, G., Liu, J., Hurst, A., Hsei, V., Wong, W-L., Ekert, R., Lawrence, D., Sherwood, S., DeForge, L., Gaudreault., Keller, G., Sliwkowski, M., Ashkenazi, A., and Presta, L. Design, Construction, and analyses of multivalent antibodies. *J. Immunol.* **170**, 4854-4861 (2003).

68. Varfolomeev, E., Kischkel, F., Martin, F., Wanh, H., Lawrence, D., Olsson, C., Tom, L., Erickson, S., French, D., Schow, P., Grewal, I. and Ashkenazi, A. Immune system development in APRIL knockout mice. Submitted.

Review articles:

1. Ashkenazi, A., Peralta, E., Winslow, J., Ramachandran, J., and Capon, D., J. Functional role of muscarinic acetylcholine receptor subtype diversity. *Cold Spring Harbor Symposium on Quantitative Biology*. **LIII**, 263-272 (1988).
2. Ashkenazi, A., Peralta, E., Winslow, J., Ramachandran, J., and Capon, D. Functional diversity of muscarinic receptor subtypes in cellular signal transduction and growth. *Trends Pharmacol. Sci.* Dec Supplement, 12-21 (1989).
3. Chamow, S., Duliege, A., Ammann, A., Kahn, J., Allen, D., Eichberg, J., Byrn, R., Capon, D., Ward, R., and Ashkenazi, A. CD4 immunoadhesins in anti-HIV therapy: new developments. *Int. J. Cancer* Supplement 7, 69-72 (1992).
4. Ashkenazi, A., Capon, and D. Ward, R. Immunoadhesins. *Int. Rev. Immunol.* **10**, 217-225 (1993).
5. Ashkenazi, A., and Peralta, E. Muscarinic Receptors. In *Handbook of Receptors and Channels*. (S. Peroutka, ed.), CRC Press, Boca Raton, Vol. I, p. 1-27, (1994).
6. Krantz, S. B., Means, R. T., Jr., Lina, J., Marsters, S. A., and Ashkenazi, A. Inhibition of erythroid colony formation in vitro by gamma interferon. In *Molecular Biology of Hematopoiesis* (N. Abraham, R. Shadduck, A. Levine F. Takaku, eds.) Intercept Ltd. Paris, Vol. 3, p. 135-147 (1994).
7. Ashkenazi, A. Cytokine neutralization as a potential therapeutic approach for SIRS and shock. *J. Biotechnology in Healthcare* **1**, 197-206 (1994).
8. Ashkenazi, A., and Chamow, S. M. Immunoadhesins: an alternative to human monoclonal antibodies. *Immunomethods: A companion to Methods in Enzymology* **8**, 104-115 (1995).
9. Chamow, S., and Ashkenazi, A. Immunoadhesins: Principles and Applications. *Trends Biotech.* **14**, 52-60 (1996).
10. Ashkenazi, A., and Chamow, S. M. Immunoadhesins as research tools and therapeutic agents. *Curr. Opin. Immunol.* **9**, 195-200 (1997).
11. Ashkenazi, A., and Dixit, V. Death receptors: signaling and modulation. *Science* **281**, 1305-1308 (1998).
12. Ashkenazi, A., and Dixit, V. Apoptosis control by death and decoy receptors. *Curr. Opin. Cell. Biol.* **11**, 255-260 (1999).

13. Ashkenazi, A. Chapters on Apo2L/TRAIL; DR4, DR5, DcR1, DcR2; and DcR3. Online Cytokine Handbook (www.apnet.com/cytokinereference/).
14. Ashkenazi, A. Targeting death and decoy receptors of the tumor necrosis factor superfamily. *Nature Rev. Cancer* **2**, 420-430 (2002).
15. LeBlanc, H. and Ashkenazi, A. Apoptosis signaling by Apo2L/TRAIL. *Cell Death and Differentiation* **10**, 66-75 (2003).
16. Almasan, A. and Ashkenazi, A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. *Cytokine and Growth Factor Reviews* **14**, 337-348 (2003).

Book:

Antibody Fusion Proteins (Chamow, S., and Ashkenazi, A., eds., John Wiley and Sons Inc.) (1999).

Talks:

1. Resistance of primary HIV isolates to CD4 is independent of CD4-gp120 binding affinity. UCSD Symposium, HIV Disease: Pathogenesis and Therapy. Greenelefe, FL, March 1991.
2. Use of immuno-hybrids to extend the half-life of receptors. IBC conference on Biopharmaceutical Half-life Extension. New Orleans, LA, June 1992.
3. Results with TNF receptor Immunoadhesins for the Treatment of Sepsis. IBC conference on Endotoxemia and Sepsis. Philadelphia, PA, June 1992.
4. Immunoadhesins: an alternative to human antibodies. IBC conference on Antibody Engineering. San Diego, CA, December 1993.
5. Tumor necrosis factor receptor: a potential therapeutic for human septic shock. American Society for Microbiology Meeting, Atlanta, GA, May 1993.
6. Protective efficacy of TNF receptor immunoadhesin vs anti-TNF monoclonal antibody in a rat model for endotoxic shock. 5th International Congress on TNF. Asilomar, CA, May 1994.
7. Interferon- γ signals via a multisubunit receptor complex that contains two types of polypeptide chain. American Association of Immunologists Conference. San Francisco, CA, July 1995.
8. Immunoadhesins: Principles and Applications. Gordon Research Conference on Drug Delivery in Biology and Medicine. Ventura, CA, February 1996.

9. Apo-2 Ligand, a new member of the TNF family that induces apoptosis in tumor cells. Cambridge Symposium on TNF and Related Cytokines in Treatment of Cancer. Hilton-Head, NC, March 1996.
10. Induction of apoptosis by Apo2 Ligand. American Society for Biochemistry and Molecular Biology, Symposium on Growth Factors and Cytokine Receptors. New Orleans, LA, June, 1996.
11. Apo2 ligand, an extracellular trigger of apoptosis. 2nd Clontech Symposium, Palo Alto, CA, October 1996.
12. Regulation of apoptosis by members of the TNF ligand and receptor families. Stanford University School of Medicine, Palo Alto, CA, December 1996.
13. Apo-3: anovel receptor that regulates cell death and inflammation. 4th International Congress on Immune Consequences of Trauma, Shock, and Sepsis. Munich, Germany, March 1997.
14. New members of the TNF ligand and receptor families that regulate apoptosis, inflammation, and immunity. UCLA School of Medicine, LA, CA, March 1997.
15. Immunoadhesins: an alternative to monoclonal antibodies. 5th World Conference on Bispecific Antibodies. Volendam, Holland, June 1997.
16. Control of Apo2L signaling. Cold Spring Harbor Laboratory Symposium on Programmed Cell Death. Cold Spring Harbor, New York. September, 1997.
17. Chairman and speaker, Apoptosis Signaling session. IBC's 4th Annual Conference on Apoptosis. San Diego, CA., October 1997.
18. Control of Apo2L signaling by death and decoy receptors. American Association for the Advancement of Science. Philladelphia, PA, February 1998.
19. Apo2 ligand and its receptors. American Society of Immunologists. San Francisco, CA, April 1998.
20. Death receptors and ligands. 7th International TNF Congress. Cape Cod, MA, May 1998.
21. Apo2L as a potential therapeutic for cancer. UCLA School of Medicine. LA, CA, June 1998.
22. Apo2L as a potential therapeutic for cancer. Gordon Research Conference on Cancer Chemotherapy. New London, NH, July 1998.
23. Control of apoptosis by Apo2L. Endocrine Society Conference, Stevenson, WA, August 1998.
24. Control of apoptosis by Apo2L. International Cytokine Society Conference, Jerusalem, Israel, October 1998.

25. Apoptosis control by death and decoy receptors. American Association for Cancer Research Conference, Whistler, BC, Canada, March 1999.
26. Apoptosis control by death and decoy receptors. American Society for Biochemistry and Molecular Biology Conference, San Francisco, CA, May 1999.
27. Apoptosis control by death and decoy receptors. Gordon Research Conference on Apoptosis, New London, NH, June 1999.
28. Apoptosis control by death and decoy receptors. Arthritis Foundation Research Conference, Alexandria GA, Aug 1999.
29. Safety and anti-tumor activity of recombinant soluble Apo2L/TRAIL. Cold Spring Harbor Laboratory Symposium on Programmed Cell Death. . Cold Spring Harbor, NY, September 1999.
30. The Apo2L/TRAIL system: therapeutic potential. American Association for Cancer Research, Lake Tahoe, NV, Feb 2000.
31. Apoptosis and cancer therapy. Stanford University School of Medicine, Stanford, CA, Mar 2000.
32. Apoptosis and cancer therapy. University of Pennsylvania School of Medicine, Philadelphia, PA, Apr 2000.
33. Apoptosis signaling by Apo2L/TRAIL. International Congress on TNF. Trondheim, Norway, May 2000.
34. The Apo2L/TRAIL system: therapeutic potential. Cap-CURE summit meeting. Santa Monica, CA, June 2000.
35. The Apo2L/TRAIL system: therapeutic potential. MD Anderson Cancer Center. Houston, TX, June 2000.
36. Apoptosis signaling by Apo2L/TRAIL. The Protein Society, 14th Symposium. San Diego, CA, August 2000.
37. Anti-tumor activity of Apo2L/TRAIL. AAPS annual meeting. Indianapolis, IN Aug 2000.
38. Apoptosis signaling and anti-cancer potential of Apo2L/TRAIL. Cancer Research Institute, UC San Francisco, CA, September 2000.
39. Apoptosis signaling by Apo2L/TRAIL. Kenote address, TNF family Minisymposium, NIH. Bethesda, MD, September 2000.
40. Death receptors: signaling and modulation. Keystone symposium on the Molecular basis of cancer. Taos, NM, Jan 2001.
41. Preclinical studies of Apo2L/TRAIL in cancer. Symposium on Targeted therapies in the treatment of lung cancer. Aspen, CO, Jan 2001.

42. Apoptosis signaling by Apo2L/TRAIL. Weizmann Institute of Science, Rehovot, Israel, March 2001.
43. Apo2L/TRAIL: Apoptosis signaling and potential for cancer therapy. Weizmann Institute of Science, Rehovot, Israel, March 2001.
44. Targeting death receptors in cancer with Apo2L/TRAIL. Cell Death and Disease conference, North Falmouth, MA, Jun 2001.
45. Targeting death receptors in cancer with Apo2L/TRAIL. Biotechnology Organization conference, San Diego, CA, Jun 2001.
46. Apo2L/TRAIL signaling and apoptosis resistance mechanisms. Gordon Research Conference on Apoptosis, Oxford, UK, July 2001.
47. Apo2L/TRAIL signaling and apoptosis resistance mechanisms. Cleveland Clinic Foundation, Cleveland, OH, Oct 2001.
48. Apoptosis signaling by death receptors: overview. International Society for Interferon and Cytokine Research conference, Cleveland, OH, Oct 2001.
49. Apoptosis signaling by death receptors. American Society of Nephrology Conference. San Francisco, CA, Oct 2001.
50. Targeting death receptors in cancer. Apoptosis: commercial opportunities. San Diego, CA, Apr 2002.
51. Apo2L/TRAIL signaling and apoptosis resistance mechanisms. Kimmel Cancer Research Center, Johns Hopkins University, Baltimore MD. May 2002.
52. Apoptosis control by Apo2L/TRAIL. (Keynote Address) University of Alabama Cancer Center Retreat, Birmingham, Ab. October 2002.
53. Apoptosis signaling by Apo2L/TRAIL. (Session co-chair) TNF international conference. San Diego, CA. October 2002.
54. Apoptosis signaling by Apo2L/TRAIL. Swiss Institute for Cancer Research (ISREC). Lausanne, Switzerland. Jan 2003.
55. Apoptosis induction with Apo2L/TRAIL. Conference on New Targets and Innovative Strategies in Cancer Treatment. Monte Carlo. February 2003.
56. Apoptosis signaling by Apo2L/TRAIL. Hermelin Brain Tumor Center Symposium on Apoptosis. Detroit, MI. April 2003.
57. Targeting apoptosis through death receptors. Sixth Annual Conference on Targeted Therapies in the Treatment of Breast Cancer. Kona, Hawaii. July 2003.
58. Targeting apoptosis through death receptors. Second International Conference on Targeted Cancer Therapy. Washington, DC. Aug 2003.

Issued Patents:

1. Ashkenazi, A., Chamow, S. and Kogan, T. Carbohydrate-directed crosslinking reagents. US patent 5,329,028 (Jul 12, 1994).
2. Ashkenazi, A., Chamow, S. and Kogan, T. Carbohydrate-directed crosslinking reagents. US patent 5,605,791 (Feb 25, 1997).
3. Ashkenazi, A., Chamow, S. and Kogan, T. Carbohydrate-directed crosslinking reagents. US patent 5,889,155 (Jul 27, 1999).
4. Ashkenazi, A., APO-2 Ligand. US patent 6,030,945 (Feb 29, 2000).
5. Ashkenazi, A., Chuntharapai, A., Kim, J., APO-2 ligand antibodies. US patent 6,046,048 (Apr 4, 2000).
6. Ashkenazi, A., Chamow, S. and Kogan, T. Carbohydrate-directed crosslinking reagents. US patent 6,124,435 (Sep 26, 2000).
7. Ashkenazi, A., Chuntharapai, A., Kim, J., Method for making monoclonal and cross-reactive antibodies. US patent 6,252,050 (Jun 26, 2001).
8. Ashkenazi, A. APO-2 Receptor. US patent 6,342,369 (Jan 29, 2002).
9. Ashkenazi, A. Fong, S., Goddard, A., Gurney, A., Napier, M., Tumas, D., Wood, W. A-33 polypeptides. US patent 6,410,708 (Jun 25, 2002).
10. Ashkenazi, A. APO-3 Receptor. US patent 6,462,176 B1 (Oct 8, 2002).
11. Ashkenazi, A. APO-2LI and APO-3 polypeptide antibodies. US patent 6,469,144 B1 (Oct 22, 2002).
12. Ashkenazi, A., Chamow, S. and Kogan, T. Carbohydrate-directed crosslinking reagents. US patent 6,582,928B1 (Jun 24, 2003).

Blast Result



NCBI

Blast 2 Sequences results

PubMed

Entrez

BLAST

OMIM

Taxonomy

Structure

BLAST 2 SEQUENCES RESULTS VERSION BLASTN 2.2.6 [Apr-09-2003]

Match: Mismatch: gap open: gap extension: x_dropoff: expect: wordsize: Filter ☒


Align

Sequence gi Homo sapiens mRNA for KIAA1402 protein, partial
 1 7243184 cds.

Length 3970 (1 .. 3970)

Sequence lcl|seq_2
 2

Length 2789 (1 .. 2789)



NOTE: The statistics (bitscore and expect value) is calculated based on the size of nr database

NOTE: If protein translation is reversed, please repeat the search with reverse strand of the query sequence

Score = 4295 bits (2234), Expect = 0.0
 Identities = 2240/2243 (99%)
 Strand = Plus / Plus

```

Query: 1182 gcagttattgagttttacttctctcttttttagtggaagacagaccataatcccagtggtg 1241
          |||
Sbjct: 1    gcagttattgagttttacttctctcttttttagtggaagacagaccataatcccagtggtg 60

Query: 1242 agtgaaattgattgtttcatttattaccgttttggtgggggtagttccgacaccttca 1301
          |||
Sbjct: 61   agtgaaattgattgtttcatttattaccgttttggtgggggtagttccgacaccttca 120

Query: 1302 cagttgaagagcaggcagaaggagttgtgaagacaggacaatcttcttggggatgctggt 1361
          |||
Sbjct: 121  cagttgaagagcaggcagaaggagttgtgaagacaggacaatcttcttggggatgctggt 180

Query: 1362 cctggaagccagcgggcctcgctctgtctttggcctcattgaccccaggttctctgggta 1421
          |||
Sbjct: 181  cctggaagccagcgggccttgctctgtctttggcctcattgaccccaggttctctgggta 240
  
```

cb

hg

b

b

e

b

cg

Blast Result

Query: 1422 aaactgaaagcctactactggcctggtgcccatcaatccattgatccttgaggctgtgcc 1481
 |||
 Sbjct: 241 aaactgaaagcctactactggcctggtgcccatcaatccattgatccttgaggctgtgcc 300

Query: 1482 cctggggcaccacacctggcagggcctaccaccatgcgactgagctccctggttggtctgc 1541
 |||
 Sbjct: 301 cctggggcaccacacctggcagggcctaccaccatgcgactgagctccctggttggtctgc 360

Query: 1542 tgcggccagcgttcccctcatcttagggctgtctctggggtgcagcctgagcctcctgc 1601
 |||
 Sbjct: 361 tgcggccagcgttcccctcatcttagggctgtctctggggtgcagcctgagcctcctgc 420

Query: 1602 gggtttcctggatccagggggagggagaagatccctgtgtcgaggctgtaggggagcgag 1661
 |||
 Sbjct: 421 gggtttcctggatccagggggagggagaagatccctgtgtcgaggctgtaggggagcgag 480

Query: 1662 gagggccacagaatccagattccagagctcggctagaccaaagtgatgaagacttcaaac 1721
 |||
 Sbjct: 481 gagggccacagaatccagattccagagctcggctagaccaaagtgatgaagacttcaaac 540

Query: 1722 cccggattgtcccctactacagggaccccaacaagccctacaagaaggtgctcaggactc 1781
 |||
 Sbjct: 541 cccggattgtcccctactacagggaccccaacaagccctacaagaaggtgctcaggactc 600

Query: 1782 ggtacatccagacagagctgggctcccgtgagcggttctggtggctgtcctgacctccc 1841
 |||
 Sbjct: 601 ggtacatccagacagagctgggctcccgtgagcggttctggtggctgtcctgacctccc 660

Query: 1842 gagctacactgtccactttggccgtggctgtgaaccgtacggtggcccatcacttccctc 1901
 |||
 Sbjct: 661 gagctacactgtccactttggccgtggctgtgaaccgtacggtggcccatcacttccctc 720

Query: 1902 ggttactctacttcaactgggcagcggggggcccggtccagcagggatgcaggtggtgt 1961
 |||
 Sbjct: 721 ggttactctacttcaactgggcagcggggggcccggtccagcagggatgcaggtggtgt 780

Query: 1962 ctcatggggatgagcggcccgctggctcatgtcagagaccctgcgccaccttcacacac 2021
 |||
 Sbjct: 781 ctcatggggatgagcggcccgctggctcatgtcagagaccctgcgccaccttcacacac 840

Query: 2022 actttggggccgactacgactggttcttcatcatgcaggatgacacatatgtgcaggccc 2081
 |||
 Sbjct: 841 actttggggccgactacgactggttcttcatcatgcaggatgacacatatgtgcaggccc 900

Query: 2082 cccgcctggcagcccttctgctggccacctcagcatcaaccaagacctgtacttaggccggg 2141
 |||
 Sbjct: 901 cccgcctggcagcccttctgctggccacctcagcatcaaccaagacctgtacttaggccggg 960

Query: 2142 cagaggagttcattggcgagggcgagcaggcccggtactgtcatgggggctttggctacc 2201
|||||
Sbjct: 961 cagaggagttcattggcgagggcgagcaggcccggtactgtcatgggggctttggctacc 1020

Query: 2202 tgttggtcacggaggtctcctgcttcgtctgcggccacatctggatggctgccgaggagaca 2261
|||||
Sbjct: 1021 tgttggtcacggaggtctcctgcttcgtctgcggccacatctggatggctgccgaggagaca 1080

Query: 2262 ttctcagtgcccgctcctgacgagtggttgacgctgcctcattgactctctgggcgtcg 2321
|||||
Sbjct: 1081 ttctcagtgcccgctcctgacgagtggttgacgctgcctcattgactctctgggcgtcg 1140

Query: 2322 gctgtgtctcacagcaccaggggcagcagtatcgctcatttgaactggccaaaaataggg 2381
|||||
Sbjct: 1141 gctgtgtctcacagcaccaggggcagcagtatcgctcatttgaactggccaaaaataggg 1200

Query: 2382 accctgagaaggaagggagctcggctttcctgagtgccctcgccgtgcaccctgtctccg 2441
|||||
Sbjct: 1201 accctgagaaggaagggagctcggctttcctgagtgccctcgccgtgcaccctgtctccg 1260

Query: 2442 aaggtaccctcatgtaccggctccacaaacgcttcagcgctctggagttggagcgggctt 2501
|||||
Sbjct: 1261 aaggtaccctcatgtaccggctccacaaacgcttcagcgctctggagttggagcgggctt 1320

Query: 2502 acagtgaaatagaacaactgcaggctcagatccggaacctgaccgtgctgacccccgaag 2561
|||||
Sbjct: 1321 acagtgaaatagaacaactgcaggctcagatccggaacctgaccgtgctgacccccgaag 1380

Query: 2562 gggaggcagggctgagctggcccggtgggctccctgctcctttcacaccacactctcgct 2621
|||||
Sbjct: 1381 gggaggcagggctgagctggcccggtgggctccctgctcctttcacaccacactctcgct 1440

Query: 2622 ttgaggtgctgggctgggactacttcacagagcagcacaccttctcctgtgcagatgggg 2681
|||||
Sbjct: 1441 ttgaggtgctgggctgggactacttcacagagcagcacaccttctcctgtgcagatgggg 1500

Query: 2682 ctcccaagtgccactacagggggctagcagggcgacgtgggtgatgcgttgagactg 2741
|||||
Sbjct: 1501 ctcccaagtgccactacagggggctagcagggcgacgtgggtgatgcgttgagactg 1560

Query: 2742 ccctggagcagctcaatcggcgctatcagccccgcctgcgcttcagaagcagcgactgc 2801
|||||
Sbjct: 1561 ccctggagcagctcaatcggcgctatcagccccgcctgcgcttcagaagcagcgactgc 1620

Query: 2802 tcaacggctatcggcgcttcgacccagcacggggcatggagtacaccctggacctgctgt 2861
|||||
Sbjct: 1621 tcaacggctatcggcgcttcgacccagcacggggcatggagtacaccctggacctgctgt 1680

Query: 2862 tggaaatgtgtgacacagcgtgggcaccggcgggccctggctcgcaggggtcagcctgctgc 2921
|||||
Sbjct: 1681 tggaaatgtgtgacacagcgtgggcaccggcgggccctggctcgcaggggtcagcctgctgc 1740

Query: 2922 ggccactgagccgggtggaaatcctacctatgccctatgtcactgaggccaccgagtg 2981
|||||
Sbjct: 1741 ggccactgagccgggtggaaatcctacctatgccctatgtcactgaggccaccgagtg 1800

Query: 2982 agctggtgctgccactcctggtggctgaagctgctgcagccccggtttcctcgaggcct 3041
|||||
Sbjct: 1801 agctggtgctgccactcctggtggctgaagctgctgcagccccggtttcctcgaggcgt 1860

Query: 3042 ttgcagccaatgtcctggagccacgagaacatgcattgctcaccctgttgctggtctacg 3101
|||||
Sbjct: 1861 ttgcagccaatgtcctggagccacgagaacatgcattgctcaccctgttgctggtctacg 1920

Query: 3102 ggccacgagaaggtggcgtggagctccagaccatttcttgggggtgaaggctgcagcag 3161
|||||
Sbjct: 1921 ggccacgagaaggtggcgtggagctccagaccatttcttgggggtgaaggctgcagcag 1980

Query: 3162 cggagttagagcgacgggtaccctgggacgaggctggcctggctcgctgtgcgagcagagg 3221
|||||
Sbjct: 1981 cggagttagagcgacgggtaccctgggacgaggctggcctggctcgctgtgcgagcagagg 2040

Query: 3222 ccccttcccaggtgcgactcatggacgtggtctcgaagaagcaccctgtggacactctct 3281
|||||
Sbjct: 2041 ccccttcccaggtgcgactcatggacgtggtctcgaagaagcaccctgtggacactctct 2100

Query: 3282 tcttcttaccacgctgtggacaaggcctgggcccgaagtcctcaaccgctgtcgcatga 3341
|||||
Sbjct: 2101 tcttcttaccacgctgtggacaaggcctgggcccgaagtcctcaaccgctgtcgcatga 2160

Query: 3342 atgccatctctggctggcaggccttctttccagtcatttccaggagttcaatcctgcc 3401
|||||
Sbjct: 2161 atgccatctctggctggcaggccttctttccagtcatttccaggagttcaatcctgcc 2220

Query: 3402 tgtcaccacagagatcaccccca 3424
|||||
Sbjct: 2221 tgtcaccacagagatcaccccca 2243

Score = 933 bits (485), Expect = 0.0
Identities = 485/485 (100%)
Strand = Plus / Plus

Query: 3486 ctccctataggggggagatttgaccggcaggccttctgcggaggggtgcttctacaacgctg 3545
|||||

Sbjct: 2305 ctctatataggggggagatttgaccggcagggttctgcggagggctgcttctacaacgctg 2364

Query: 3546 actacctggcggcccgagcccggtggcaggtgaactggcaggccaggaagaggaggaag 3605
|||||

Sbjct: 2365 actacctggcggcccgagcccggtggcaggtgaactggcaggccaggaagaggaggaag 2424

Query: 3606 ccctggaggggctggaggtgatggatgttttcctccggttctcagggtccacctctttc 3665
|||||

Sbjct: 2425 ccctggaggggctggaggtgatggatgttttcctccggttctcagggtccacctctttc 2484

Query: 3666 gggccgtagagccagggtggtgcagaagttctccctgcgagactgcagcccacgggtca 3725
|||||

Sbjct: 2485 gggccgtagagccagggtggtgcagaagttctccctgcgagactgcagcccacgggtca 2544

Query: 3726 gtgaagaactctaccaccgctgccgcctcagcaacctggaggggctagggggccgtgcc 3785
|||||

Sbjct: 2545 gtgaagaactctaccaccgctgccgcctcagcaacctggaggggctagggggccgtgcc 2604

Query: 3786 agctggctatggctctctttgagcaggagcaggccaatagcacttagcccgctgggggc 3845
|||||

Sbjct: 2605 agctggctatggctctctttgagcaggagcaggccaatagcacttagcccgctgggggc 2664

Query: 3846 cctaacctcattacctttcctttgtctgcctcagccccaggaagggaaggcaagatggt 3905
|||||

Sbjct: 2665 cctaacctcattacctttcctttgtctgcctcagccccaggaagggaaggcaagatggt 2724

Query: 3906 ggacagatagagaattgttgctgtatTTTTTaaatatgaaaatgttattaaacatgtctt 3965
|||||

Sbjct: 2725 ggacagatagagaattgttgctgtatTTTTTaaatatgaaaatgttattaaacatgtctt 2784

Query: 3966 ctgcc 3970

||||

Sbjct: 2785 ctgcc 2789

CPU time: 0.02 user secs. 0.01 sys. secs 0.03 total secs.

Lambda	K	H
1.33	0.621	1.12

Gapped



Lambda	K	H
1.33	0.621	1.12

Matrix: blastn matrix:1 -2
Gap Penalties: Existence: 5, Extension: 2
Number of Hits to DB: 20
Number of Sequences: 0
Number of extensions: 20
Number of successful extensions: 2
Number of sequences better than 10.0: 1
Number of HSP's better than 10.0 without gapping: 1

h cb hg b b e b cg

Number of HSP's successfully gapped in prelim test: 0
Number of HSP's that attempted gapping in prelim test: 0
Number of HSP's gapped (non-prelim): 2
length of query: 3970
length of database: 9,156,315,655
effective HSP length: 26
effective length of query: 3944
effective length of database: 9,156,315,629
effective search space: 36112508840776
effective search space used: 36112508840776
T: 0
A: 0
X1: 6 (11.5 bits)
X2: 26 (50.0 bits)
S1: 12 (23.8 bits)
S2: 22 (43.0 bits)

NCBI Sequence Viewer

Search for

Limits Show:

Links

☐ 1: AB037823. Homo sapiens mRNA...[gi:7243184]

LOCUS AB037823 3970 bp mRNA linear PRI 14-MAR-2000
 DEFINITION Homo sapiens mRNA for KIAA1402 protein, partial cds.
 ACCESSION AB037823
 VERSION AB037823.1 GI:7243184
 KEYWORDS .
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (sites)
 AUTHORS Nagase,T., Kikuno,R., Ishikawa,K.I., Hirosawa,M. and Ohara,O.
 TITLE Prediction of the coding sequences of unidentified human genes.
 XVI. The complete sequences of 150 new cDNA clones from brain which
 code for large proteins in vitro
 JOURNAL DNA Res. 7 (1), 65-73 (2000)
 MEDLINE 20181126
 PUBMED 10718198
 REFERENCE 2 (bases 1 to 3970)
 AUTHORS Ohara,O., Nagase,T. and Kikuno,R.
 TITLE Direct Submission
 JOURNAL Submitted (31-JAN-2000) Osamu Ohara, Kazusa DNA Research Institute,
 Laboratory of DNA Technology; 1532-3 Yana, Kisarazu, Chiba
 292-0812, Japan (E-mail:cdnainfo@kazusa.or.jp,
 URL:http://www.kazusa.or.jp/huge/, Tel:+81-438-52-3913,
 Fax:+81-438-52-3914)
 FEATURES
 source Location/Qualifiers
 1..3970
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="hk09846"
 /tissue_type="brain"
 /clone_lib="pBluescriptII SK plus"
 gene 1..3970
 /gene="KIAA1402"
 CDS <1466..3832
 /gene="KIAA1402"
 /note="Start codon is not identified."
 /codon_start=1
 /product="KIAA1402 protein"
 /protein_id="BAA92640.1"
 /db_xref="GI:7243185"
 /translation="SLRLCPWGTHLAGPTTMRLLSLLALLRPALPLILGLSLGCSLSL
 LRVSWIQGEDEPCVEAVGERGGPQNPDSSRLDQSDDFKPRIVPYRDPNPKYKKV
 LRTRYIQTELGSRRERLLVAVLTSLATLSTLAVAVNRTVAHHFPRLLYFTGQRGARAPA
 GMQVVSHGDERPAWLMSETLRHLHTHFGADYDWFIMQDDTYVQAPRLAALAGHLSIN
 QDLYLGRAEEFIGAGEQARYCHGGFGYLLSRLLLLRLRPHLDGCRGDILSARPDEWLG

cb hg e e e fcg c e e e b c e e

RCLIDSLGVGCVSQHQGQQYRSFELAKNRDPEKEGSSAFLSAFAVHPVSEGTLMYRLH
 KRFSALELERAYSEIEQLQAQIRNLTVLTPEGEAGLSWPVGLPAPFTPHSRFEVLGWD
 YFTEQHTFSCADGAPKCPLQGASRADVGDALETALEQLNRRYQPRLRFOQRLLNGYR
 RFDPPARGMEYTLDLLLECVTQRGHRRLARRVSLRLPLSRVEILPMPYVTEATRVQLV
 LPLLVAEAAAAPAFLEAFAANVLEPREHALLTLLLVYGPREGGRGAPDPFLGVKAAAA
 ELERRYPGTRLAWLAVRAEAPSQVRLMDVVSKKHPVDTLFFLTTVWTRPGFEVLNRCR
 MNAISGWQAFFPVHFQEFNPALSPQRSPPGPPGAGPDPPSPPGADPSRGAPIGGRFDR
 QASAEKCFYNADYLAARARLAGELAGQEEEEALEGLEVMDFLRFSGLHLFRAVEPGL
 VQKFSLRDCSPRLSEELYHRCRLSNLEGLGGRAQLAMALFEQEQA NST"

BASE COUNT 664 a 1237 c 1202 g 867 t

ORIGIN

```

1 aggggctgtg aggtggcagc ggctgcagcg gcggagccgg cgccctcagcg ggcactgggg
61 tctgttcccc cttccccgtc cctgtccct gccaggcggc tgcgggacgc cgctcttggg
121 cccacgcct ccgccccgcc cctcccggg acgccgggag accccggccg tctttatcc
181 ggtgtccgcc ggcccccgcc cctgaaaccc gggcctcctc ccgagggcc ttgggcgtcc
241 ctctgggtcc tgcgtcgcgc gcctcgatgc tgtctctggc gcggcctccg ctcccgcga
301 ctggcctgag aacgaggtct gtgccccagt ctcccagccg cgacctccga ccccgctcg
361 cagaacgacc cgagctgggc tcccagagcc cttctcagc agcccgggtga cgtggccagt
421 ttatttctgt ttgagacga acggcgaaga ctgcgcgcgc gtcttcgttc tagggctaga
481 cttggtctct gatcgccgag aggtagcgca ggggctgtgg gccccggca ggggtcctgt
541 cggaagctgg ccgcgttct gtttgcttc ccaggacctt ggcattgtct ctagttgctg
601 cttgtgctct ctctttgct ttggtttgct tcatttggcc cctggggccc tggtaaaacc
661 aggcaccgaa tcgctcgac acagagttcc agtccccgcc tgcgtctcc tcagcagctg
721 ggggtccgag gagaatgccc tgcaagtgg ctccatcgcc catggcgctc ctgagaggct
781 tgcagtgtcg agtcaccgat ctacctcatt cgggtgggca gaacttatgt gtgccatgcg
841 agtggctcca gaccgctcct gagtgggagg aggggttcct gtagccgttg cgtcttctca
901 aacacgggga gcagagtaga aagaggtctt gggcccttc cttgtgcca ccgggcctgc
961 cgcagtggct cagcagcccc ttcagtagcc cgctgagga ccgatgccag aggcaggcat
1021 tcttccggaa agggccactg aggcaggctc cggctcctct ggttggggct gttgtttga
1081 tggatcgtgt gcttttccct tacctcttat cacttgctgt catctgttga cttaggccca
1141 gtctgcagat gtgtgtagtg ttcttttttg ggttagcttt ggcagtattg agttttactt
1201 cctcctcttt ttagtggaag acagaccata atcccagtg gtgtgaaatt gattgtttca
1261 tttattaccg ttttggctgg gggtaggttc cgacaccttc acagttgaag agcaggcaga
1321 aggagttgtg aagacaggac aatcttcttg gggatgctgg tcctggaagc cagcgggctc
1381 cgctctgtct ttggcctcat tgacccagg ttctctggtt aaaactgaaa gcctactact
1441 ggccctggtc ccacaaatcc attgatcctt gaggtgtgct ccctggggca cccacctggc
1501 agggcctacc accatgcgac tgagctccct gttggctctg ctgaggccag cgcttccct
1561 catcttaggg ctgtctctgg ggtgcagcct gagcctcctg cgggttctct ggaatccagg
1621 ggagggagaa gatccctgtg tcgaggctgt aggggagcga ggagggccac agaattccaga
1681 ttccagagct cggctagacc aaagtgatga agacttcaaa ccccgattg tccctacta
1741 cagggacccc aacaagccct acaagaaggt gctcaggact cggtagatcc agacagagct
1801 gggctccgct gagcggttgc tgggtgctgt cctgacctcc cgagctacac tgtccacttt
1861 ggccgtggct gtgaaccgta cgggtggcca tcacttccct cggttactct acttactgg
1921 gcagcggggg gcccgggctc cagcagggat gcagggtgtg tctcatgggg atgagcggcc
1981 cgcctggctc atgtcagaga ccctgcgcca cttcacaca cactttgggg ccgactacga
2041 ctggttcttc atcatgcagg atgacacata tgtcagggcc cccgcctgg cagcccttgc
2101 tggccacctc agcatcaacc aagacctgta cttaggccgg gcagaggagt tcattggcgc
2161 aggcgagcag gcccggtact gtcaggggg ctttggctac ctggtgtcac ggagtctcct
2221 gcttcgtctg cggccacatc tggatggctg ccgaggagac attctcagtg cccgtcctga
2281 cgagtggctt ggacgctgcc tcattgactc tctggcgctc ggctgtgtct cacagcacca
2341 ggggcagcag tatcgctcat ttgaactggc caaaaatagg gaccctgaga aggaagggag
2401 ctcggtcttc ctgagtgctc tcgcggtgca ccctgtctcc gaaggatccc tcatgtaccg
2461 gctccacaaa cgcttcagcg ctctggagt ggagcgggct tacagtgaat tagaacaact
2521 gcaggctcag atccggaaac tgaccgtgct gacccccgaa ggggagggcag ggctgagctg
2581 gccggttggg ctccctgctc ctttcacacc acactctcgc tttgaggtgc tgggctggga
2641 ctacttcaca gagcagcaca cttctcctg tgcagatggg gctcccaagt gccactaca
2701 gggggctagc agggcggaac tgggtgatgc gttggagact gccctggagc agctcaatcg
2761 gcgctatcag cccgcctgc gcttcagaa gcagcgactg ctcaacggct atcgcgctt
2821 cgaccagca cggggcatgg agtacacctt ggacctgctg ttggaatgtg tgacacagcg
2881 tgggcaccgg cgggccctgg ctgcagggt cagcctgctg cggccactga gccgggtgga

```